Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
Keep the sparks coming! Delegates of the conference have access to on-demand content until the end of October 2021.
This updated edition is a great reference for anyone working in multinational product development and marketing.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 12 February 2014 | By Alexander Gaffney, RAC,
Two facilities maintained and run by a manufacturer of active pharmaceutical ingredients (API) exhibited serious violations of current good manufacturing practices (CGMPs), the US Food and Drug Administration (FDA) said in a Warning Letter issued this week.
The API manufacturer, CBS Chem, was subject to two separate inspections in 2013, one for its facility in Tempe, AZ and another for its Tuen Min, Hong Kong facility.
While FDA inspectors alleged that both facilities had problems, those alleged to have taken place at the Tempe facility were particularly jarring.
In one instance reported in the Warning Letter, an FDA inspector tested a container that was labeled as having a specific excipient. However, FDA's testing determined that the container was full of a mix of at least five different ingredients, and apparently active ingredients, as FDA said they were used to treat specific unspecified diseases.
"The unacceptable practices that resulted in this mislabeling incident can pose a severe hazard to consumers," FDA wrote.
The same facility was also chided for failing to implement a system by which it could confirm the identity of APIs received there.
"[Y]our firm failed to provide basic documents that must be retained including those with the identity and address of the original manufacturer (e.g., COAs, other records with critical information regarding the ingredients)," FDA wrote, adding that the approval of the quality unit personnel was also missing.
Similar problems were found at CBS Chem's Hong Kong facility, FDA said. The firm was found to have maintained incomplete records for its APIs, failed to transfer quality and regulatory information to its customers and improperly maintained its packaging and holding areas to avoid mix-ups.
In addition, the company reportedly failed to have a quality unit responsible for assuring product quality or reviewing and approving CGMP documents.
FDA recommended that the company hire the services of a third-party consultant to bring it up to federal production standards.
Warning Letter
Tags: warning letter, Latest News, Excipient, cGMP, API
Regulatory Focus newsletters
All the biggest regulatory news and happenings.